{
    "organizations": [],
    "uuid": "67a08afb09b64b24de8be4b4ad3d7959625be599",
    "author": "",
    "url": "https://www.reuters.com/article/brief-protalix-announces-positive-result/brief-protalix-announces-positive-results-from-phase-ii-clinical-trial-of-oprx-106-for-treatment-of-ulcerative-colitis-idUSASC09RYF",
    "ord_in_thread": 0,
    "title": "BRIEF-Protalix Announces Positive Results From Phase II Clinical Trial Of OPRX-106 For Treatment Of Ulcerative Colitis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "  in 7 minutes BRIEF-Protalix Announces Positive Results From Phase II Clinical Trial Of OPRX-106 For Treatment Of Ulcerative Colitis Reuters Staff 1 Min Read   Protalix Biotherapeutics Inc: * PROTALIX BIOTHERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE II CLINICAL TRIAL OF OPRX-106 FOR THE TREATMENT OF ULCERATIVE COLITIS * PROTALIX BIOTHERAPEUTICS INC - KEY EFFICACY ENDPOINTS OF STUDY WERE MET * PROTALIX BIOTHERAPEUTICS INC - OPRX-106 WAS SAFE AND WELL TOLERATED WITH ONLY MILD TO MODERATE ADVERSE EVENTS IN STUDY * PROTALIX BIOTHERAPEUTICS INC - NO ANTI-DRUG ANTIBODIES WERE DETECTED IN STUDY  ",
    "published": "2018-03-13T13:11:00.000+02:00",
    "crawled": "2018-03-13T13:21:23.013+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "minute",
        "announces",
        "positive",
        "result",
        "phase",
        "ii",
        "clinical",
        "trial",
        "treatment",
        "ulcerative",
        "colitis",
        "reuters",
        "staff",
        "min",
        "read",
        "protalix",
        "biotherapeutics",
        "inc",
        "protalix",
        "biotherapeutics",
        "announces",
        "positive",
        "result",
        "phase",
        "ii",
        "clinical",
        "trial",
        "treatment",
        "ulcerative",
        "colitis",
        "protalix",
        "biotherapeutics",
        "inc",
        "key",
        "efficacy",
        "endpoint",
        "study",
        "met",
        "protalix",
        "biotherapeutics",
        "inc",
        "safe",
        "well",
        "tolerated",
        "mild",
        "moderate",
        "adverse",
        "event",
        "study",
        "protalix",
        "biotherapeutics",
        "inc",
        "antibody",
        "detected",
        "study"
    ]
}